Clinical trial
Investigation of the Seropersistence of TBE Antibodies and the Booster Response…
NCT00161785 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00161785 |
|---|---|
| Title | Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 Years |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Tick-borne Encephalitis |
| Intervention type | Biological |
| Interventions | FSME-IMMUN 0.5ml |
| Enrollment | 340 |
| Start date | Jun 1, 2004 |
| Completion | Jul 1, 2005 |
| First posted | Sep 13, 2005 |
| Last update posted | May 21, 2015 |
| Countries | Poland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: